Search clinical trials for: GSK 257049

Total 1348 results

GlaxoSmithKline

Completed

Characterisation of the Immune Responses of 2 Experimental Malaria Vaccines

Malaria

Belgium
GlaxoSmithKline
The PATH Malaria Vaccine Initiative (MVI)

Completed

Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate Malaria Vaccine Lots in Children

Malaria

Nigeria
GlaxoSmithKline

Completed

Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children

Malaria

Gabon
GlaxoSmithKline
Crucell Holland BV; The PATH Malaria Vaccine Initiative (MVI)

Completed

Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults

Malaria

United States
GlaxoSmithKline

Completed

Partially-blind (Observer-blind) Study of Safety and Immunogenicity of Two Malaria Vaccines in Ghanaian Children

Malaria

Ghana
GlaxoSmithKline

Completed

Efficacy of RTS,S/AS01 Vaccine Against Episodes of Malaria Due to P. Falciparum Infection in Children.

Malaria

Kenya, Tanzania
GlaxoSmithKline

Completed

Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants

Malaria | Malaria Vaccines

Tanzania
GlaxoSmithKline
The PATH Malaria Vaccine Initiative (MVI)

Completed

Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa

Malaria

Ghana, Kenya, Mozambique, Tanzania, Burkina Faso, Gabon, Malawi
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen

Malaria

Ghana, Tanzania, Gabon
GlaxoSmithKline
The PATH Malaria Vaccine Initiative (MVI)

Completed

Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants

Malaria

Malawi
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)

Malaria | Malaria Vaccines

Ghana, Burkina Faso
GlaxoSmithKline

Completed

Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children

Malaria

Kenya
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Recruiting

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

Systemic Lupus Erythematosus

United States, Spain, China, Korea, Republic of, Argentina, Bulgaria, Chile, Greece, Japan, Mauritius, Mexico, Moldova, Republic of, Poland, South Africa, Australia, Colombia, Philippines, Serbia
GlaxoSmithKline

Completed

Single Dose Escalation First Time in Human PK Study

Infections, Bacterial

Australia
GlaxoSmithKline
Aeras

Completed

Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342

Tuberculosis

Belgium
GlaxoSmithKline

Completed

An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa

Malaria

Burkina Faso, Kenya, Tanzania
GlaxoSmithKline

Completed

A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy Subjects

Crohn's Disease

United States
GlaxoSmithKline

Completed

Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age

Herpes Zoster

United States
GlaxoSmithKline

Terminated

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease

Tuberculosis

Taiwan, Estonia
GlaxoSmithKline

Completed

Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older

Influenza

Spain, United States
GlaxoSmithKline

Completed

Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old

Influenza

Thailand, Philippines
GlaxoSmithKline

Completed

Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier

Herpes Zoster

United States
GlaxoSmithKline

Recruiting

Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Neoplasms

United States, Spain, Italy, Netherlands, Canada, Australia, Germany, United Kingdom
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

Study of M5049 in Healthy Japanese and Caucasian Participants

Healthy

United Kingdom
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

Study of M5049 in CLE and SLE Participants

Systemic Lupus Erythematosus | Cutaneous Lupus Erythematosus

Spain, Bulgaria, Germany, Moldova, Republic of, North Macedonia, Ukraine
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy Adults

Tuberculosis

Philippines
GlaxoSmithKline

Completed

Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults

Influenza

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)

Coronavirus Disease 2019

United States, Brazil, Philippines
Merck KGaA, Darmstadt, Germany

Completed

Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of M5049 in Healthy Participants

Healthy

Germany
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults

Influenza

Germany
GlaxoSmithKline

Completed

Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine

Respiratory Disorders

Australia
Shaare Zedek Medical Center

Terminated

Response to Hepatitis B Vaccine in Celiac Disease Patients

Celiac Disease

Israel
GlaxoSmithKline

Completed

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

Infections, Meningococcal

United States
GlaxoSmithKline
PATH

Completed

A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults

Malaria

United States
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast Cancer

Neoplasms, Breast

France, Belgium, Peru, Italy, Colombia
GlaxoSmithKline

Completed

Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)

Infections, Papillomavirus | Papillomavirus Vaccines

Belgium
GlaxoSmithKline

Completed

Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants

Infections, Streptococcal

Germany, Czechia, Sweden, Poland
Brigham and Women's Hospital
GlaxoSmithKline; Ionis Pharmaceuticals, Inc.

Withdrawn

The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart

Amyloidosis
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults.

Influenza

Czechia
GlaxoSmithKline

Completed

Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™

Infections, Streptococcal

Nigeria, Mali
University of Chile
Bill and Melinda Gates Foundation

Unknown

Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine (IPV002ABMG)

Polio

Chile
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity & Safety of an Investigational Influenza Vaccine in Adults

Influenza

France
Radboud University Medical Center
GlaxoSmithKline

Completed

Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)

Influenza | Herpes Zoster

Netherlands
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Study of M5049 in DM and PM Participants (NEPTUNIA)

Dermatomyositis | Polymyositis

United States, Italy, Spain, Greece, Czechia, United Kingdom, Poland
Arto Palmu
GlaxoSmithKline

Completed

Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage (FinIPcarr)

Pneumococcal Infections

Finland
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children

Influenza

Australia, Singapore
GlaxoSmithKline

Completed

Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults

Herpes Zoster

Australia
GlaxoSmithKline

Completed

Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds

Infections, Meningococcal

Thailand, Panama, Philippines

3

Subscribe